To stop or not to stop: That is the question, but what is the answer?

AIDS

Volumn 16, Issue 5, 2002, Pages 787-789

  Hogg, Robert S ^a   Havlir, Diane ^a,b   Miller, Veronica ^a,c   Montaner, Julio S G ^a  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy; Disease progression; HIV; Treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COHORT ANALYSIS; DRUG EFFICACY; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS RESISTANCE;

HIV INFECTIONS; HUMANS;

EID: 0037192530     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200203290-00015     Document Type: Editorial

References (34)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. A randomized, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients. The INCAS Trial. Italy, The Netherlands, Canada and Australia Study
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
4. Improved survival among HIV-infected individuals following the initiation of triple combination antiretroviral regimens
5. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997
6. Decay characteristics of HIV-1 infected compartments during combination therapy
7. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
8. Latent infection of CD4+ T-cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
9. Adherence to triple therapy and viral load response
10. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
11. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance due to HIV protease inhibitors
12. Lipodystrophy-associated morphologic and metabolic abnormalities in a large population-based observational HIV/AIDS treatment database in a context of free and universal access to antiretroviral therapies
13. Patterns of heart disease in HIV infected patients with and without opportunistic infections: A color Doppler echocardiographic study
14. Interactions among drugs for HIV and opportunistic infections
15. Rates of disease progression stratified by baseline CD4+ T cell count and HIV-1 RNA levels among HIV-1 infected patients initiating triple drug therapy
16. Long-term survival after initiation of antiretroviral therapy
17. CD4+ lymphocyte level is better than HIV-1 plasma viral load in determining when to initiate HAART
18. Late initiation of antiretroviral therapy (at CD4+ Lymphocytes < 200 Cells/ml) is associated with increased risk of death
19. Structured treatment interruption in antiretroviral management of HIV-1
20. Control of HIV despite the discontinuation of antiretroviral therapy
21. Immune control of HIV-1 after early treatment of acute infection
22. Virological and immunological effects of treatment interruptions in HIV-infected patients with treatment failure
23. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
24. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen
25. Virologic and immunologic consequences of discontinuing combination antiretroviral drug therapy in HIV-infected patients with detectable viremia
26. Impact of occasional short interruptions of HAART on the progression of HIV infection: Results from a cohort study
27. Increase in breadth and frequency of CTL responses after structured therapy interruptions in individuals treated with HAART during Acute HIV-1 Infection
28. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection
29. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection
30. Host factors in the pathogenesis of HIV disease: Implications for therapeutic strategies
31. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society - USA Panel
32. The British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy